Novo Nordisk: The Danish pharmaceutical giant lowers annual targets again – Blockbusters lose momentum!
Reading Time: 3 minutes
Novo Nordisk is at a turning point: The Danish global leader in diabetes and obesity drugs, celebrated for its billion-dollar blockbusters Wegovy and Ozempic, must temper expectations. The global hype surrounding weight-loss medications has catapulted the company’s market value to dizzying heights and sent the pharmaceutical industry into a gold rush. Yet, just now, amidst this boom, the third quarter presents a setback. The Danes are once again lowering their annual targets. "Consistently difficult business with diabetes medications and weight-loss...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
